Three EU Tecfidera Generics Recommended As Biogen Battles For Exclusivity
Mylan, Polpharma And Neuraxpharm Backed Amid Regulatory Tussle
Executive Summary
Following a years-long back-and-forth to establish exclusivity protection for its Tecfidera multiple-sclerosis treatment in Europe, Biogen has ultimately seen the CHMP recommend three generic versions to receive pan-European marketing authorization.
You may also be interested in...
Biogen Sees Interest In Potential Biosimilars Deal
As Biogen provided an update on a potential sale of its biosimilars business – with the firm “engaged with multiple interested parties” – it also revealed Q2 sales and offered insights into off-patent competition to its Tysabri and Tecfidera brands.
Biogen Will Assert New Tecfidera Patent Amid Hexal Germany Launch
Biogen has conceded that generics to its Tecfidera treatment for relapsing remitting multiple sclerosis may launch “at risk” in the EU, after the US-based player was recently granted further patent protection until 2028.
Neuraxpharm Boosts Branded Business With Established Sanofi Portfolios
CNS specialist Neuraxpharm has purchased two of Sanofi’s product portfolios, substantially expanding the number of branded products it has to offer.